DiBella’s sub shop scouting for Indianapolis locations
DiBella's Old Fashioned Submarines, a chain of gourmet sandwich shops based in Rochester, N.Y., is scouting for locations for between six and eight new restaurants in central Indiana.
DiBella's Old Fashioned Submarines, a chain of gourmet sandwich shops based in Rochester, N.Y., is scouting for locations for between six and eight new restaurants in central Indiana.
Scientists with Roche Holding AG, the parent company of Indianapolis-based Roche Diagnostics Corp., may have found a way to overcome a blood barrier that keeps drugs from directly entering the brain, potentially opening new pathways to attack Alzheimer’s disease.
Roche Diagnostics Corp. landed an $11.4 million contract to provide laboratory testing services at military hospitals in the Washington, D.C., area.
In a monthly feature that runs in the first issue of the month, through October, IBJ is identifying influential players in eight different industry categories. Formidable brainpower sums up the individuals included in our list of Who’s Who in Life Sciences.
When customers are few, it’s time for a price cut. With only 177 Hoosiers signed up for the federal Pre-Existing Condition Insurance Plan created by the 2010 health reform law, the U.S. Department of Health and Human Services decided to drop premiums 26 percent. Now adults aged 45-54 can buy into the plan for $284 per month or $295 for a health savings account. The plan was created by the Patient Protection and Affordable Care Act (a.k.a. health care reform) to provide coverage to Americans until 2014, when health insurers will no longer be allowed to deny coverage based on pre-existing conditions. Nationwide, only 18,000 people have signed up for the plan—far below expectations. The department cut prices 40 percent or more in 17 states. In addition, the government will begin paying insurance agents and brokers this fall for connecting eligible participants to the Pre-Existing Condition Insurance Plan.
Roche Diagnostics Corp. landed an $11.4 million contract to provide laboratory testing services at military hospitals in the Washington, D.C., area. Switzerland-based Roche operates its North American diagnostic headquarters out of Indianapolis, where it employs 2,900 people. The new contract with the Medcom Contracting Center North Atlantic was awarded May 19 and will run until Sept. 30, but has four one-year renewal options. Roche equipment will conduct tests of blood and other fluids at the Walter Reed National Military Medical Center in Bethesda, Md., as well as the new Fort Belvoir Community Hospital in Virginia. Roche Diagnostics sells mid- and high-volume laboratory analyzers, such as its new cobas 8000 machine, to hospitals and academic medical centers. It also sells diagnostict machines for use by physicians in their offices and for other small-scale situations. In all, Roche's professional diagnostics business accounts for one-third of its total North American sales, or about $880 million. Roche Diagnostics also makes tests for diabetes and genetic traits, as well as gene sequencers and other diagnostic equipment. Its North American sales totaled $2.6 billion last year.
International Medical Group Inc., an Indianapolis-based seller of international health insurance policies, had signed a marketing partnership with a subsidiary of Marsh & McLennan Companies, the New York-based insurance and consulting firm. IMG’s products, which provide coverage for and coordination of medical care to individuals and groups while traveling abroad, will be marketed nationally under the Gateway brand name.
Monday's Supreme Court decision is a victory for companies that collaborate with universities in research. Indianapolis-based Eli Lilly and Co. was among the companies that supported Roche.
Swiss health care giant Roche Holding AG has selected its diagnostics division in Indianapolis as the site for a new North America human resources center, a move that will add 50 employees to its local operations.
The Indianapolis Star is halting publication of its free weekly stand-alone Metromix section after the June 23 edition, but some of the content intended to appeal to young readers will be posted online.
The recently announced 16 Tech District adds a new tool to Indianapolis’ strong life sciences arsenal.
Marsh Supermarkets is reoccupying a portion of its long-vacant headquarters building and has snagged a plum tenant to sublease most of the rest of the space.
Eli Lilly and Co.’s foray into combination drugs is well-timed because the company could take advantage of some the world’s most successful biotech medicines, which are about to see their patents expire.
We often forget that as a society there are real advantages to working (and investing) together for a common purpose.
Former Eli Lilly and Co. vice president Richard Dimarchi, BioCrossroads President David Johnson, angel investor Oscar Moralez and Purdue University Senior Vice President Alan Rebar discuss issues ranging from the depth of the life sciences industry in Indiana to venture capital and Purdue’s Discovery Park.
Rochester Medical Implants plans to move operations from Rochester to Noblesville in October. The company has 28 employees.
Researchers at the Indiana University School of Medicine plan to launch a large clinical trial of an experimental two-drug combination for treating late-stage ovarian cancer. The drug combo produced a positive effect in 70 percent of patients in a Phase 2 trial and the IU researchers said they may have discovered biomarkers that could help identify women who would respond best to the therapy. The therapy combines two chemotherapy agents, decitabine with carboplatin. The IU researchers, led by Dr. Daniela Matei, are using it for women who have become resistant to carboplatin after multiple rounds of chemotherapy. IU is now seeking grant funding for a Phase 3 trial, in which the combo therapy will be compared against other approved therapies for ovarian cancer. Their research has been supported by the National Institutes of Health, National Cancer Institute, Walther Cancer Foundation in Indianapolis and the Ovarian Cancer Research Foundation.
DePuy Orthopaedics Inc. plans to spend $27 million on manufacturing and research equipment to grow its orthopedic implant operation in Warsaw, Ind. The expansion will add no jobs to DePuy’s 1,100-person work force, but the Warsaw City Council has approved a 10-year property tax abatement on the equipment. DePuy spokeswoman Jessica Masuga told The Journal Gazette of Fort Wayne that the equipment will improve efficiency. DePuy is a subsidiary of New Jersey-based Johnson & Johnson.
West Lafayette-based Endocyte Inc. raised about $66.8 million in a secondary public offering of nearly 6.7 million shares of company stock. Shares for the offering, which began in mid-July, were priced at $12.26 each. Endocyte, which also has offices in Indianapolis, said it intends to seek permission to sell its ovarian cancer drug in Europe on a limited basis. The decision to proceed came after consultation with the European Medicines Agency and written advice from the regulators, Endocyte said in April. Endocyte shares had more than doubled in price after its initial public offering in February, before sliding in the recent market-wide decline in stocks.
Rochester Medical Implants will move its 28 employees from Rochester to Noblesville. Fulton Economic Development Corp. director Terry Lee said company officials attributed the decision to an inability to recruit needed employees to Rochester and better proximity to customers in the Indianapolis area. The Rochester Sentinel reported that a company co-owner had previously discussed plans for expanding on its eight-acre site in that city. Lee said some of the company's workers plan on transferring to the new location, with the move expected to happen by October. Rochester is about 75 miles north of Noblesville.
Roche Diagnostics Corp., which runs its U.S. headquarters out of Indianapolis, got a boost Wednesday when the U.S. Food and Drug Administration approved a new genetic test to go along with a new Roche melanoma drug.
New drug for metastatic melanoma packaged with genetic test should help Roche sell more of its cobas 4800 laboratory testing systems.
A high-living Manhattan businesswoman accused of an audacious fraud that cost some of central Indiana’s marquee companies millions of dollars has cut a deal with prosecutors that would ensure she spends no more than 31 months in prison.
Every business sector has influential players, whether they are in the public eye or wield their influence behind the scenes. This month, IBJ zeroes in on Health Care and Benefits.
Executives at Roche Diagnostics expect the wave of austerity measures being taken by western governments—including the United States—to as much as double its sales of fluid- and DNA-based tests in the next three years.